Foundation Medicine Inc. (FMI) was founded in 2010 and became an independent affiliate of the Roche Group in 2018 following the complete acquisition of the organisation by Roche.
FMI is committed to driving advancements in cancer genomics through its portfolio of comprehensive genomic profiling (CGP) tests. Its CGP tests analyse more than 300 genes known to drive cancer growth, to help match patients with treatment options most appropriate for them. It aims to make CGP the global standard of care so that insights from this approach can enable more informed treatment decisions and help accelerate the development of new cancer therapies.
FMI has over 1,700 employees and has locations throughout North America and Germany, with its headquarters being located in Cambridge, Massachusetts.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.